Get started
Author

Tracey Hammett

Observed names: T. Hammett, Tracey C Hammett
ORCID: 0009-0003-3059-3652
Observed ORCID: 0009-0003-3059-3652
OpenAlex ID: A5029955834
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
2015 · Kenneth S. Thress, Roz Brant, et al. · Lung Cancer · 497
Clinical Relevance of Dissolution Testing in Quality by Design
2008 · Paul A. Dickinson, Wang Wang Lee, et al. · The AAPS Journal · 138
PDF
DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.
2022 · Manish R. Patel, Melissa Lynne Johnson, et al. · Journal of Clinical Oncology · 23
Targeting T regulatory (T reg ) cells in immunotherapy-resistant cancers
2024 · Pavlina Spiliopoulou, Paramjit Kaur, et al. · Cancer Drug Resistance · 17
PDF
Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.
2024 · Anna Maria Di Giacomo, Matteo Simonelli, et al. · Journal of Clinical Oncology · 7
PDF
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291.
2014 · Kenneth Thress, Roz Brant, et al. · Journal of Clinical Oncology · 7
513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
2021 · M.L. Johnson, T. Doi, et al. · Annals of Oncology · 6
PDF
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
2026 · Anna Maria Di Giacomo, Matteo Simonelli, et al. · Nature Communications · 5
PDF
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
2024 · Davide Melisi, Alberto Quinzii, et al. · Journal of Clinical Oncology · 5
PDF
164P Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
2024 · A.M. Di Giacomo, M. Simonelli, et al. · Immuno-Oncology Technology · 3
PDF
First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).
2023 · Anna Maria Di Giacomo, Federica Santangelo, et al. · Journal of Clinical Oncology · 2
192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study
2022 · A.M. Di Giacomo, F. Santangelo, et al. · Immuno-Oncology Technology · 2
A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).
2025 · Paul D. Nathan, Anna Maria Di Giacomo, et al. · Journal of Clinical Oncology · 1
626P Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
2024 · A.M. Di Giacomo, M. Simonelli, et al. · Annals of Oncology · 1
PDF
Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma
2023 · Carmelo Carlo-Stella, Michael Lahn, et al. · Blood · 1
Highly Selective Allosteric Modulator of the Phosphoinositide 3‐Kinase Delta (PI3Kδ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma
2023 · C. Carlo‐Stella, C. Tarantelli, et al. · Hematological Oncology · 1
PDF
1181 Roginolisib plus dostarlimab with or without docetaxel reverts immune suppression and shows clinical activity in immunotherapy-resistant non-small cell lung cancer (NSCLC)
2026 · Reinier Wener, Aitor Azkàrate Martínez, et al. · Journal for ImmunoTherapy of Cancer
PDF
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) – A Trial in Progress
2026 · Jasson Villarreal Hernandez, Javier Octavio Díaz Carbonero, et al. · OncoTargets and Therapy
PDF
453P Proteomic evidence of on-target activity of cambritaxestat (IOA-289) in patients with metastatic pancreatic ductal adenocarcinoma
2026 · D. Melisi, G. Di Conza, et al. · Annals of Oncology
PDF
218eTiP The PULMO-01 phase I/IIa study of roginolisib in combination with dostarlimab, with or without docetaxel, in patients with advanced non-squamous NSCLC who have progressed on standard of care therapy
2026 · R. Wener, A. Azkárate Martínez, et al. · ESMO Open
PDF
Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)
2025 · Alessandro Vannucchi, Chiara Paoli, et al. · Blood
Abstract 2055: Molecular profiling of the PI3Kδ inhibitor roginolisib in metastatic uveal melanoma and its correlation with clinical outcomes
2025 · Alessio Bevilacqua, Tan Ziyang, et al. · Cancer Research
131P Safety and clinical efficacy of roginolisib (IOA-244): The first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ)
2023 · A.M. Di Giacomo, M. Simonelli, et al. · Immuno-Oncology Technology
PDF
P1114: Highly Selective Allosteric Modulator of the Phosphoinositide 3-kinase Delta (pi3kδ) Roginolisib (ioa-244) in a Dose Escalation Study of Patients With Refractory/relapsed Follicular Lymphoma (fl)
2023 · Carmelo Carlo-Stella, Michael Lahn, et al. · HemaSphere
119P Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study
2023 · A.M. Di Giacomo, P. Mason, et al. · ESMO Open
Works count: 26
Citation count: 716
H-index: 6
I10-index: 4
Year
Topic
Type